DOCSLIB.ORG

ESMO E-Learning Metastatic Castrate-Resistant Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ESMO E-Learning Metastatic Castrate-Resistant Prostate Cancer METASTATIC CASTRATE- RESISTANT PROSTATE CANCER TREATMENT (MCRPC) Fabricio Racca GU, CNS and Sarcoma Programme, Oncology Department Vall d’Hebron University Hospital, Barcelona, Spain AGENDA First-line treatment in mCRPC patients: Standard of Care Androgen Biosynthesis Inhibitors (ABIs) Second generation antiandrogens Docetaxel Radium 223 Novel hormonal therapies Immunotherapy Targeted therapies Failed trials Conclusions Siegel RL, et al., CA Cancer J Clin 2017;67:7–30. © 2017 American Cancer Society. With permission from John Wiley and Sons. SINCE 2010 A PLETHORA OF NEW TRIALS HAVE SHOWN BENEFIT IN MCRPC Trial / agent approved Disease state Comparator Hazard ratio P value IMPACT Chemo-näive CRPC Placebo 0.77 0.032 (Provenge vaccine) 2010 COU-AA-302 Placebo Chemo-naïve CRPC UK UK (Abiraterone acetate) 2012 Prednisone Pre-docetaxel ALSYPMCA (Radium 223) 2013 BSC 0.74 <0.00046 CRPC PREVAIL (Enzalutamide) 2014 Chemo-naïve CRPC Placebo 0.71 <0.0001 Mitoxantrone TAX327 (Docetaxel) 2004 Chemo-naïve CRPC 0.76 0.009 Prednisone Mitoxantrone TROPIC (Cabazitaxel) 2010 Post-docetaxel CRPC 0.70 <0.0001 Prednisone COU-AA-301 Post-docetaxel Placebo 0.65 <0.0001 (Abiraterone acetate) 2010 CRPC Prednisone Post-docetaxel ALSYPMCA (Radium 223) 2013 BSC 0.71 <0.00046 CRPC Post-docetaxel AFFIRM (Enzalutamide) 2012 BSC 0.63 <0.0001 CRPC ANDROGEN BIOSYNTHESIS INHIBITORS (ABIS) ABIRATERONE ACETATE + PREDNISONE Cholesterol Desmolase Renin Deoxy- Pregnenolone Progesterone Corticosterone Aldosterone corticosterone CYP17 17α-hydroxylaseX 11β-Hydroxylase ACTH 17α-OH- 17α –OH- 11-Deoxy- Cortisol pregnenolone progesterone cortisol CYP17 C17,20X-lyase 5α-reductase DHEA Androstenedione Testosterone DHT CYP19: aromatase Estradiol Adapted from Attard G, et al., J Clin Oncol 26(28), 2008: 4563-71. Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. ABIRATERONE: PHASE III (COU-AA-301) 1195 patients with R Efficacy endpoints (ITT) Abiraterone 1000 mg daily progressive, mCRPC A N Prednisone 5 mg BID Primary endpoint: Failed 1 or D N=797 OS (25% improvement; 2 chemotherapy O HR 0.8) regimens, one of M Secondary endpoints (ITT): which contained I docetaxel S Placebo daily TTPP E Prednisone 5 mg BID rPFS D n=398 2:1 PSA response Phase 3, multinational, multicentre, randomised, double-blind, placebo-controlled study (147 sites in 13 countries; USA, Europe, Australia, Canada) Stratification according to: ECOG performance status (0-1 vs. 2) Worst pain over previous 24 hours (BPI short form; 0-3 [absent] vs. 4-10 [present]) Prior chemotherapy (1 vs. 2) Type of progression (PSA only vs. radiographic progression with or without PSA progression) de Bono JS, et al., N Eng J Med 2011;364 21:1995-2005. UPDATED ANALYSIS (775 EVENTS): OS BENEFIT OF A AA INCREASED FROM 3.9 TO 4.6 MONTHS AA 100 Placebo HR (95% CI): 0.74 (0.64-0.86) 80 p < 0.0001 AA median OS (95% CI): 60 15.8 months (14.8-17.0) 40 Survival (%) Placebo median OS (95% CI): 20 11.2 months (10.4-13.1) 0 0 6 12 18 24 30 Time to death (months) AA 797 657 473 273 15 0 Placebo 398 306 183 100 6 0 Median duration of follow-up: 20.2 months Median duration of treatment: 8 months with AA vs. 4 months with placebo Reprinted from The Lancet Oncology 2012; 13 (10), Fizazi K, et al., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, 983–92. Copyright 2012, with permission from Elsevier. ABIRATERONE: PHASE III (COU-AA-302) Efficacy endpoints Patients R A Primary: Progressive chemo-naïve N AA 1000 mg daily rPFS by central review mCRPC patients D Prednisone 5 mg BID OS (n = 1088) O (n = 546) M Secondary: Asymptomatic or mildly I symptomatic S Time to opiate use (cancer- E Placebo daily related pain) D Prednisone 5 mg BID Time to initiation of (n = 542) chemotherapy 1:1 Time to ECOG-PS deterioration TTPP Phase 3 multicentre, randomised, double-blind, placebo-controlled study conducted at 151 sites in 12 countries; USA, Europe, Australia, Canada Stratification by ECOG performance status 0 vs. 1 Ryan C, et al., N Engl J Med 2013;368(2)138-148. STATISTICALLY SIGNIFICANT IMPROVEMENT IN RPFS PRIMARY ENDPOINT Reprinted from Eur Urol, 66(5), Rathkopf D, et al., Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302), 815–25. Copyright 2014 with permission from the European Association of Urology. COU-AA-302: OVERALL SURVIVAL Reprinted from The Lancet Oncology 2015; 16(2), Ryan C, et al., Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study; 152–60. Copyright 2015, with permission from Elsevier. SAFETY OF LONG TERM TREATMENT OF CHEMO-NAÏVE MCRPC PATIENTS WITH AA + P FOR ≥4 YEARS AEs in COU-AA-302 patients who received AA + P for ≥4 years AEs in COU-AA-302 patients who received AA + P for ≥4 years vs. <4 years either early (0-12 Months) or late (36-48 months) AA + P ≥4 years AA + P <4 years During 0-12 months of During 36-48 months (n=41) (n=505) treatment (n=41) of treatment (n=41) Any grade, n (%) 41(100) 500 (99.8) Any grade, n (%) 41(100) 39 (95) Grade 3/4, n (%) 23 (56) 267 (53) Grade 3/4, n (%) 9 (22) 6 (15) Any Grade Any Grade Any Any Grade 3b Grade 3b grade* 3-4 grade 3-4 gradea grade Fatigue 27 (66) 1 (2) 217 (43) 15 93) Fatigue 11 (27) 0 8 (20) 0 Diarrhoea 21 (51) 1 (2) 116 (23) 7 (1) Diarrhoea 6 (15) 0 7 (17) 0 Arthralgia 20 (49) 2 (5) 153 (31) 9 (2) Arthralgia 7 (17) 1 (2) 5 (12) 0 Back pain 20 (49) 1 (2) 180 (36) 17 (3) Back pain 7 (17) 1 (2) 5 (12) 0 Peripheral Peripheral 17 (42) 0 132 (26) 3 (<1) 10 (24) 0 4 (10) 0 oedema oedema *>40% cut-off. a. >15% cut-off; b.There were no grade 4 or 5 AEs. Conclusion 41 of 546 patients in COU-AA-302 continued AA + P treatment for ≥4 years As expected, efficacy measures were improved for AA + P ≥4 years vs. AA + P <4 years group There were no new safety signals or signs of cumulative toxicity over time with AA + P Carles J, et al., Ann Oncol 2016;27(6):243–65. 740P. 12 SECOND GENERATION ANTIANDROGENS ENZALUTAMIDE Reprinted from Clin Cancer Res, 2013, 19(6):1335–9, Hoffman-Censits J, Kelly WK, Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer, with permission from AACR. AFFIRM A phase 3 trial of Enzalutamide vs. placebo in post-chemotherapy treated castration-resistant prostate cancer (CRPC) Patient population: R Primary endpoint: A Enzalutamide 1199 patients with progressive N Overall Survival CRPC D 160 mg daily O n = 800 *Failed docetaxel M chemotherapy I S E Placebo D n = 399 2:1 *Glucocorticoids were not required but allowed. Scher HI, et al., N Engl J Med 2012;367(13):1187-97. OVERALL SURVIVAL From N Engl J Med, Scher HI, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy, 367(13):1187–97. Copyright © 2012 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. TIME TO PSA PROGRESSION AND RADIOGRAPHIC PROGRESSION- FREE SURVIVAL Time to PSA progression Radiographic progression-free survival From N Engl J Med, Scher HI, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy, 367(13):1187–97. Copyright © 2012 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. PREVAIL A phase 3 trial of Enzalutamide vs. placebo in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) Patient population: R A Enzalutamide 1717 patients with N Co-Primary endpoints: progressive mCRPC D 160 mg daily O n = 872 Overall Survival Asymptomatic M I rPFS Chemotherapy naïve S E Placebo D n = 845 1:1 Beer TM, et al., N Engl J Med 2014;371(5),424–33. PREVAIL: CO-PRIMARY ENDPOINTS Rate of rPFS: 65% (Enza) vs.14% (Placebo) - HR 0.19 (95% CI, 0.15 to 0.23; P<0.001) Median OS: 32.4 months (Enza) vs. 30.2 (Placebo) HR 0.71 (95% CI, 0.60 to 0.84; P<0.001) From N Engl J Med, Beer TM, et al., Enzalutamide in metastatic prostate cancer before chemotherapy, 371 (5), 424–433. Copyright © 2014 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. DOCETAXEL DOCETAXEL IS STANDARD IN FIRST-LINE CPRC Docetaxel plus prednisone or mitoxantrone Docetaxel and estramustine compared plus prednisone for advanced PC1 with mitoxantrone and prednisone for Median survival (mos) HR P-value advanced refractory prostate cancer2 Combination 0.83 0.04 Docetaxel q3w 18.9 0.76 0.009 Docetaxcel qw 17.4 0.91 0.36 Mitoxantrone 16.5 n/a n/a HR: 0.80 (95% CI 0.67, 0.97) 1. From N Engl J Med, Tannock IF, et al., Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, 351:1502–12. Copyright © 2004 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society; 2. From N Engl J Med, Petrylak DP, et al. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, 351:1513–20. Copyright © 2004 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. PHASE III CLINICAL TRIALS SHOWING DOCETAXEL IMPACT ON SURVIVAL Docetaxel-based phase III trials % with Time to PSA Study Regimen ORR paliative progression Survival response response (months) SWOG Docetaxel + Estramustine 17 50 17 6 18 Mitoxantrone + PDN 10 27 11 3 16 TAX 327 Docetaxel (3w) + PDN 12 45 35 7.9 18.9 Docetaxel (w) + PDN 8 48 31 8.2 17.4 Mitoxantrone + PDN 7 32 22 7.8 16.5 Sternberg C, et al., Progress in the treatment of advanced prostate cancer.
Load more

Recommended publications
  • WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C07K 16/28 (2006.01) A61K 31/4166 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 59/595 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/065841 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 12 December 2017 (12.12.2017) patent (Rule 4.1 7(H)) — as to the applicant's entitlement to claim the priority of the (25) Filing Language: English earlier application (Rule 4.17(Hi)) (26) Publication Langi English — of inventorship (Rule 4.1 7(iv)) (30) Priority Data: Published: 62/433,158 12 December 2016 (12.12.2016) US — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, P T RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: a Review of Clinical Effectiveness and Cost- Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: June 6, 2019 Report Length: 30 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness. Ottawa: CADTH; 2019 Jun. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • INFOLETTER 5 – COVID-19 04 April 2020
    INFOLETTER 5 – COVID-19 04 April 2020 Content overview Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)……………………………………………………………………………………….............3 EMA advice on the use of NSAIDs for Covid-19 ................................................................................... 9 Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement ................................................................................................................................................ 9 Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study ............................10 Italian Society of Interventional Cardiology (GISE) Position Paper for Cath lab‐specific Preparedness Recommendations for Healthcare providers in case of suspected, probable or confirmed cases of COVID‐19 .............................................................................................................10 ECMO for ARDS due to COVID-19 ........................................................................................................11 The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2........................................................................................12 Performance of VivaDiagTM COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19
    [Show full text]
  • Abiraterone Induces SLCO1B3 Expression in Prostate Cancer Via Microrna‑579‑3P Roberto H
    www.nature.com/scientificreports OPEN Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA‑579‑3p Roberto H. Barbier1, Edel M. McCrea1, Kristi Y. Lee1, Jonathan D. Strope1, Emily N. Risdon1, Douglas K. Price1, Cindy H. Chau1 & William D. Figg1,2* Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority. The organic anion polypeptide 1B3 (OATP1B3, encoded by SLCO1B3) transporter has been shown to transport androgens into prostate cancer cells. In this study we observed and investigated the mechanism of induction of SLCO1B3 by abiraterone. Prostate cancer cells (22Rv1, LNCaP, and VCAP) were treated with anti‑ androgens and assessed for SLCO1B3 expression by qPCR analysis. Abiraterone treatment increased SLCO1B3 expression in 22Rv1 cells in vitro and in the 22Rv1 xenograft model in vivo. MicroRNA profling of abiraterone‑treated 22Rv1 cells was performed using a NanoString nCounter miRNA panel followed by miRNA target prediction. TargetScan and miRanda prediction tools identifed hsa‑miR‑ 579‑3p as binding to the 3′‑untranslated region (3′UTR) of the SLCO1B3. Using dual luciferase reporter assays, we verifed that hsa‑miR‑579‑3p indeed binds to the SLCO1B3 3′UTR and signifcantly inhibited SLCO1B3 reporter activity. Treatment with abiraterone signifcantly downregulated hsa‑miR‑579‑3p, indicating its potential role in upregulating SLCO1B3 expression. In this study, we demonstrated a novel miRNA‑mediated mechanism of abiraterone‑induced SLCO1B3 expression, a transporter that is also responsible for driving androgen deprivation therapy resistance. Understanding mechanisms of abiraterone resistance mediated via diferential miRNA expression will assist in the identifcation of potential miRNA biomarkers of treatment resistance and the development of future therapeutics.
    [Show full text]
  • Androgen Receptor Inhibitor Enhances the Antitumor Effect Of
    Published OnlineFirst September 19, 2018; DOI: 10.1158/1535-7163.MCT-18-0234 Small Molecule Therapeutics Molecular Cancer Therapeutics Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response Ahrum Min1,2, Hyemin Jang1, Seongyeong Kim1, Kyung-Hun Lee1,2,3,4, Debora Keunyoung Kim5, Koung Jin Suh1,4,6, Yaewon Yang1,4,7, Paul Elvin8, Mark J. O'Connor9, and Seock-Ah Im1,2,3,4 Abstract The androgen receptor (AR) is expressed in 60%–70% of MDA-MB-468 cells by AZD3514 occurred in parallel breast cancers regardless of estrogen receptor status, and has with the suppression of ATM–chk2 axis activation, and the been proposed as a therapeutic target in breast cancers that suppression of NKX3.1 by AZD3514 was found to result retain AR. In this study, the authors aimed to investigate a from AZD3514-induced TOPORS upregulation and a resul- new treatment strategy using a novel AR inhibitor AZD3514 tant increase in NKX3.1 degradation. The study shows in breast cancer. AZD3514 alone had a minimal antiproli- posttranslational regulation of NKX3.1 via TOPORS upre- ferative effect on most breast cancer cell lines irrespective of gulation by AZD3514-induced ATM inactivation–increased AR expression level, but it downregulated the expressions of olaparib sensitivity in AR-positive and TOPORS-expressing DNA damage response (DDR) molecules, including ATM breast cancer cells, and suggests the antitumor effect of and chk2, which resulted in the accumulation of damaged AZD3514/olaparib cotreatment is caused by compromised DNA in some breast cancer cells.
    [Show full text]
  • Targeting the Androgen Receptor in Triple-Negative Breast Cancer: Current Perspectives
    Journal name: OncoTargets and Therapy Article Designation: Review Year: 2017 Volume: 10 OncoTargets and Therapy Dovepress Running head verso: Mina et al Running head recto: Targeting the androgen receptor in TNBC open access to scientific and medical research DOI: http://dx.doi.org/10.2147/OTT.S126051 Open Access Full Text Article REVIEW Targeting the androgen receptor in triple-negative breast cancer: current perspectives Alain Mina1 Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype associated with frequent Rachel Yoder2 recurrence and metastasis. Unlike hormone receptor-positive subtypes, treatment of TNBC is Priyanka Sharma1 currently limited by the lack of clinically available targeted therapies. Androgen signaling is necessary for normal breast development, and its dysregulation has been implicated in breast 1Division of Medical Oncology, Department of Internal Medicine, tumorigenesis. In recent years, gene expression studies have identified a subset of TNBC that is University of Kansas Medical Center, enriched for androgen receptor (AR) signaling. Interference with androgen signaling in TNBC 2 Westwood, University of Kansas is promising, and AR-inhibiting drugs have shown antitumorigenic activity in preclinical and Cancer Center, Kansas City, KS, USA proof of concept clinical studies. Recent advances in our understanding of androgenic signaling in TNBC, along with the identification of interacting pathways, are allowing development of the next generation of clinical trials with AR inhibitors. As novel AR-targeting agents are developed and evaluated in clinical trials, it is equally important to establish a robust set of For personal use only. biomarkers for identification of TNBC tumors that are most likely to respond to AR inhibition.
    [Show full text]
  • ( 12 ) United States Patent ( 10 ) Patent No .: US 10,786,501 B2 Rajasekhar Et Al
    US010786501B2 ( 12 ) United States Patent ( 10 ) Patent No .: US 10,786,501 B2 Rajasekhar et al . ( 45 ) Date of Patent : * Sep . 29 , 2020 ( 54 ) TREATMENT OF PROSTATE CANCER 7,056,927 B2 6/2006 Guo et al . 7,176,211 B2 2/2007 Guo et al . 7,300,935 B2 11/2007 Cho et al. ( 71 ) Applicants : Myovant Sciences GmbH , Basel ( CH ) ; 7,419,983 B2 9/2008 Guo et al . Takeda Pharmaceutical Company 7,569,570 B2 8/2009 Furuya et al . Limited , Osaka ( JP ) 8,058,280 B2 11/2011 Cho et al. 8,735,401 B2 5/2014 Cho et al. ( 72 ) Inventors : Vijaykumar Reddy Rajasekhar, Apple 8,765,948 B2 7/2014 Gallagher et al . 9,346,822 B2 5/2016 Cho et al. Valley, CA (US ); Brendan Mark 9,382,214 B2 7/2016 Gallagher et al . Johnson , Chapel Hill , NC ( US ) ; David 9,422,310 B2 8/2016 Beaton et al . B. MacLean , Cambridge , MA (US ); 9,758,528 B2 9/2017 Fukuoka et al . Lynn Seely , San Mateo , CA ( US ) ; Paul 10,150,778 B2 12 /2018Mwa N. Mudd , Jr., Cary, NC ( US ) 10,449,191 B2 10/2019 Rajasekhar et al . 2009/0048273 Al 2/2009 Furuya et al . 2011/0172249 Al 7/2011 Kamikawa et al . ( 73 ) Assignees : Myovant Sciences GmbH , Basil ( CH ) ; 2017/0210753 A1 7/2017 Fukuoka et al . Takeda Pharmaceutical Company 2018/0036250 A1 2/2018 Yamane et al. Limited , Osaka ( JP ) 2018/0319816 A1 11/2018 Miwa et al. 2019/0055261 A1 2/2019 Miwa ( * ) Notice : Subject to any disclaimer , the term of this 2019/0262346 Al 8/2019 Johnson et al .
    [Show full text]
  • Drug Repurposing for Triple-Negative Breast Cancer
    Journal of Personalized Medicine Review Drug Repurposing for Triple-Negative Breast Cancer 1, 1,2, 1,2 Marta Ávalos-Moreno y, Araceli López-Tejada y, Jose L. Blaya-Cánovas , Francisca E. Cara-Lupiañez 1,2 , Adrián González-González 1,2 , Jose A. Lorente 1,3 , Pedro Sánchez-Rovira 2 and Sergio Granados-Principal 1,2,* 1 GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avenida de la Ilustración, 18016 Granada, Spain; [email protected] (M.Á.-M.); [email protected] (A.L.-T.); [email protected] (J.L.B.-C.); [email protected] (F.E.C.-L.); [email protected] (A.G.-G.); [email protected] (J.A.L.) 2 UGC de Oncología Médica, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; [email protected] 3 Department of Legal Medicine, School of Medicine—PTS—University of Granada, 18016 Granada, Spain * Correspondence: sgranados@fibao.es or [email protected]; Tel.: +34-651-55-79-21 These authors contributed equally to this study. y Received: 24 September 2020; Accepted: 28 October 2020; Published: 29 October 2020 Abstract: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer which presents a high rate of relapse, metastasis, and mortality. Nowadays, the absence of approved specific targeted therapies to eradicate TNBC remains one of the main challenges in clinical practice. Drug discovery is a long and costly process that can be dramatically improved by drug repurposing, which identifies new uses for existing drugs, both approved and investigational. Drug repositioning benefits from improvements in computational methods related to chemoinformatics, genomics, and systems biology.
    [Show full text]
  • Androgen-AR Axis in Primary and Metastatic Prostate Cancer: Chasing Steroidogenic Enzymes for Therapeutic Intervention
    Pippione et al. J Cancer Metastasis Treat 2017;3:328-61 DOI: 10.20517/2394-4722.2017.44 Journal of Cancer Metastasis and Treatment www.jcmtjournal.com Topic: How does the prostate cancer microenvironment affect the metastatic Open Access process and/or treatment outcome? Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention Agnese C. Pippione1, Donatella Boschi1, Klaus Pors2, Simonetta Oliaro-Bosso1, Marco L. Lolli1 1Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy. 2Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK. Correspondence to: Dr. Marco L. Lolli, Department of Science and Drug Technology, University of Torino, Via Pietro Giuria 9, 10125 Torino, Italy. E-mail: [email protected]; Dr. Simonetta Oliaro-Bosso, Department of Science and Drug Technology, University of Torino, Via Pietro Giuria 9, 10125 Torino, Italy. E-mail: [email protected] How to cite this article: Pippione AC, Boschi D, Pors K, Oliaro-Bosso S, Lolli ML. Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention. J Cancer Metastasis Treat 2017;3:328-61. ABSTRACT Article history: Androgens play an important role in prostate cancer (PCa) development and progression. Received: 21 Jun 2017 Although androgen deprivation therapy remains the front-line treatment for advanced First Decision: 16 Aug 2017 prostate cancer, patients eventually relapse with the lethal form of the disease. The prostate Revised: 4 Sep 2017 tumor microenvironment is characterised by elevated tissue androgens that are capable of Accepted: 26 Oct 2017 activating the androgen receptor (AR).
    [Show full text]
  • Androgen Receptor Antagonism Drives Cytochrome P450 17A1 Inhibitor Efficacy in Prostate Cancer
    Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer John D. Norris, … , William D. Figg, Donald P. McDonnell J Clin Invest. 2017;127(6):2326-2338. https://doi.org/10.1172/JCI87328. Research Article Endocrinology Therapeutics The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC). Recently, however, it has been reported that CYP17 inhibitors can interact directly with the androgen receptor (AR). A phase I study recently reported that seviteronel, a CYP17 lyase–selective inhibitor, ædemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another study showed seviteronel’s direct effects on AR function. This suggested that seviteronel may have therapeutically relevant activities in addition to its ability to inhibit androgen production. Here, we have demonstrated that CYP17 inhibitors, with the exception of orteronel, can function as competitive AR antagonists. Conformational profiling revealed that the CYP17 inhibitor– bound AR adopted a conformation that resembled the unliganded AR (apo-AR), precluding nuclear localization and DNA binding. Further, we observed that seviteronel and abiraterone inhibited the growth of tumor xenografts expressing the clinically relevant mutation AR-F876L and that this activity could be attributed entirely to competitive AR antagonism. The results of this study suggest that the ability of CYP17 inhibitors to directly antagonize the AR may contribute to their clinical efficacy in CRPC. Find the latest version: https://jci.me/87328/pdf RESEARCH ARTICLE The Journal of Clinical Investigation Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer John D.
    [Show full text]